CLIN.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 Dec 1970 @ 19:00):

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally...

Stats
Today's Volume	1.79M
Average Volume	1.68M
Market Cap	0.00
EPS	£0.0264 ( 2020-09-29 )
Last Dividend	£5.46 ( 2021-12-02 )
Next Dividend	£0 ( N/A )
P/E	0.410
ATR14	£0 (0.00%)

Clinigen Group PLC Correlation

10 Most Positive Correlations
ARE.L	0.952
3USS.L	0.942
3ULS.L	0.939
XPD.L	0.936
MNZS.L	0.93
PBLT.L	0.925
GAW.L	0.91
GPH.L	0.891
IGE.L	0.878
AIBG.L	0.876

10 Most Negative Correlations
YGEN.L	-0.965
DNM.L	-0.942
ECHO.L	-0.941
FRG.L	-0.932
EXR.L	-0.932
3NGL.L	-0.931
SIXH.L	-0.925
GIF.L	-0.921
VCAP.L	-0.911
MAST.L	-0.911

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clinigen Group PLC Financials

Annual	2021
Revenue:	£523.60M
Gross Profit:	£197.90M (37.80 %)
EPS:	£0.233

FY	2021
Revenue:	£523.60M
Gross Profit:	£197.90M (37.80 %)
EPS:	£0.233

FY	2020
Revenue:	£504.30M
Gross Profit:	£220.00M (43.62 %)
EPS:	£0.103

FY	2019
Revenue:	£456.90M
Gross Profit:	£182.30M (39.90 %)
EPS:	£0.0400

Financial Reports:

No articles found.

Clinigen Group PLC Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)	£0 (N/A)

Clinigen Group PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 9.57 - good (95.68%) | Divividend Growth Potential Score: 4.52 - Potential for dividend initiation, but uncertain (9.63%)

Information

First Dividend	£0.600	2013-03-06
Last Dividend	£5.46	2021-12-02
Next Dividend	£0	N/A
Payout Date	2022-01-04
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	£45.62	--
Avg. Dividend % Per Year	0.20%	--
Score	3.37	--
Div. Sustainability Score	9.57
Div.Growth Potential Score	4.52
Div. Directional Score	7.04	--

Next Divdend (Est)
(2024-10-28)

£0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.37

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2013	£0	0.00%
2014	£0	0.00%
2015	£0	0.00%
2016	£0	0.00%
2017	£0	0.00%
2018	£5.60	0.64%
2019	£6.70	0.91%
2020	£7.61	0.83%
2021	£7.61	1.09%
2022	£0	0.00%
2023	£0	0.00%
2024	£0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for LSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHOE.L	Dividend Knight	2023-07-13	Annually	10	2.57%
INSE.L	Dividend Junior	2023-10-12	Annually	12	0.60%
BRFI.L	Dividend King	2023-06-15	Semi-Annually	13	2.65%
OXIG.L	Dividend Knight	2023-08-03	Semi-Annually	32	0.64%
FEV.L	Dividend Knight	2023-09-21	Semi-Annually	32	1.54%
AA4.L	Dividend King	2023-07-13	Semi-Annually	9	7.97%
STEM.L	Dividend Knight	2023-11-09	Annually	19	1.82%
KITW.L	Dividend Knight	2023-07-13	Semi-Annually	4	2.78%
CFX.L	Dividend Knight	2023-09-14	Annually	33	0.44%
PSON.L	Dividend King	2023-08-10	Semi-Annually	32	1.90%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0579	1.500	8.84	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0284	1.200	9.05	10.00	[0 - 0.3]
returnOnEquityTTM	0.0679	1.500	-0.357	-0.535	[0.1 - 1]
payoutRatioTTM	0.333	-1.000	6.67	-6.67	[0 - 1]
currentRatioTTM	1.752	0.800	6.24	4.99	[1 - 3]
quickRatioTTM	0.480	0.800	-1.884	-1.507	[0.8 - 2.5]
cashRatioTTM	0.480	1.500	8.45	10.00	[0.2 - 2]
debtRatioTTM	0.393	-1.500	3.45	-5.18	[0 - 0.6]
interestCoverageTTM	5.00	1.000	9.26	9.26	[3 - 30]
operatingCashFlowPerShareTTM	0.348	2.00	9.88	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.130	2.00	9.93	10.00	[0 - 20]
debtEquityRatioTTM	0.937	-1.500	6.25	-9.38	[0 - 2.5]
grossProfitMarginTTM	0.378	1.000	7.03	7.03	[0.2 - 0.8]
operatingProfitMarginTTM	0.112	1.000	9.77	9.77	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.108	1.000	-0.511	-0.511	[0.2 - 2]
assetTurnoverTTM	0.491	0.800	-0.0576	-0.0460	[0.5 - 2]
Total Score				9.57

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.63	1.000	6.10	0	[1 - 100]
returnOnEquityTTM	0.0679	2.50	-0.229	-0.535	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.130	2.00	9.96	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.348	2.00	9.88	10.00	[0 - 30]
payoutRatioTTM	0.333	1.500	6.67	-6.67	[0 - 1]
pegRatioTTM	25.76	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				4.52

Clinigen Group PLC

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.